SCHEMBL17655673

SCHEMBL17655673

O=c1c2cc(Cl)ccc2sc2c(Cl)nc3ccccc3c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.58
TOP1 P11387 1/20 0.53
TOP2A P11388 1/20 0.53
PIM1 P11309 6/20 0.42
PIM2 Q9P1W9 4/20 0.42
MAPT P10636 3/20 0.40
THRB P10828 1/20 0.40
GUSB P08236 1/20 0.38
LMNA P02545 1/20 0.38
NPC1 O15118 2/20 0.37
MEN1 O00255 1/20 0.37
HCRTR1 O43613 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
KMT2A Q03164 1/20 0.37
RELA Q04206 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16339008 0.90 TOP1 (0.64) KDM4ETOP1TOP2AMAPTTHRB
SCHEMBL17655671 0.87 KDM4E (0.52) KDM4ETOP1TOP2APIM1PIM2
SCHEMBL21450906 0.87 TOP1 (0.43) KDM4ETOP1TOP2AMAPTTHRB
SCHEMBL21450975 0.87 ALDH1A1 (0.46) KDM4ETOP1TOP2APIM1PIM2
SCHEMBL16339120 0.87 KDM4E (0.52) KDM4ETOP1TOP2APIM1PIM2
SCHEMBL21451018 0.84 TOP1 (0.41) KDM4ETOP1TOP2APIM1PIM2
SCHEMBL21450818 0.84 KDM4E (0.59) KDM4ETOP1TOP2AMAPTLMNA
SCHEMBL21450985 0.84 TOP1 (0.44) KDM4ETOP1TOP2AMAPTNPC1
SCHEMBL16339385 0.84 KDM4E (0.49) KDM4ETOP1TOP2APIM1PIM2
SCHEMBL21451040 0.84 TOP1 (0.41) KDM4ETOP1TOP2AMAPTGUSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
WO-2019191896-A1 FMS-LIKE TYROSINE KINASE INHIBITORS 3SM BIOTRON INC. (CN) 2019-10-10 WO disclosed
EP-3002287-B1 Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors NAT DEFENSE MEDICAL CENTER (TW) 2018-01-31 EP disclosed
EP-3002287-A1 Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors National Defense Medical Center (TW) 2016-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332476-B2 Fms-like tyrosine kinase inhibitors FLT3, FLT4, FLT1 KDM4E 1341/4885TOP1 2980/4885TOP2A 2701/4885
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS FLT3, FLT4, FLT1 KDM4E 1341/4885TOP1 2980/4885TOP2A 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.